1. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease
- Author
-
Sumit Sarkar, Aida G Guzman Lopez, Srinivasulu Chigurupati, Susan M. Burks, Nancy P. Gomez-Crisostomo, Bonnie L. Robinson, Claudia Escudero-Lourdes, Joseph P. Hanig, James Raymick, Sherry A. Ferguson, and Elvis Cuevas
- Subjects
0301 basic medicine ,Parkinson's disease ,medicine.drug_class ,Dopamine ,Medicine (miscellaneous) ,Pharmacology ,Neuroprotection ,Taurochenodeoxycholic Acid ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Animals ,Humans ,Medicine ,Dopamine transporter ,Alpha-synuclein ,030109 nutrition & dietetics ,Nutrition and Dietetics ,Tyrosine hydroxylase ,biology ,Bile acid ,business.industry ,Dopaminergic Neurons ,General Neuroscience ,Autophagy ,Parkinson Disease ,Tauroursodeoxycholic acid ,General Medicine ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,Neuroprotective Agents ,chemistry ,biology.protein ,business ,030217 neurology & neurosurgery - Abstract
Parkinson's disease (PD) is a progressive motor disease of unknown etiology. Although neuroprotective ability of endogenous bile acid, tauroursodeoxycholic acid (TUDCA), shown in various diseases, including an acute model of PD,the potential therapeutic role of TUDCA in progressive models of PD that exhibit all aspects of PD has not been elucidated. In the present study, mice were assigned to one of four treatment groups: (1) Probenecid (PROB); (2) TUDCA, (3) MPTP + PROB (MPTPp); and (3) TUDCA + MPTPp.
- Published
- 2020